Skip to main content
SpringerLink
Log in

GlycA is a Novel Marker of Inflammation Among Non-Critically Ill Hospitalized Patients with Type 2 Diabetes

  • Published:
Inflammation Aims and scope Submit manuscript

Abstract

GlycA is a nuclear magnetic resonance-derived signal that originates from oligosaccharide chains of acute phase proteins. The objective of this study is to characterize GlycA levels in hospitalized non-critically ill patients with type 2 diabetes. This study evaluated traditional and novel (GlycA) inflammatory markers among 121 patients who were stratified by admission diagnoses: congestive heart failure (CHF), cardiac non-CHF (CARD), infection (INF), and other (OTH). HbA1c was similar across groups (8.0–9.2 %, p = 0.20). Inflammatory markers were elevated but varied significantly across disease categories, with the highest values of interleukin-6 (IL-6), c-reactive protein (CRP), and GlycA in the INF group and the highest tumor necrosis factor-α and intracellular adhesion molecule-1 levels in CHF group. GlycA was associated with higher IL-6 and CRP, lower hemoglobin, and lower glomerular filtration rate. GlycA and other inflammatory markers were not significantly associated with admission glucose or HbA1c. Among hospitalized non-critically ill patients with type 2 diabetes, GlycA was highest in INF patients and was associated with IL-6 and CRP. None of the markers were significant predictors of glucose control.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

CRP:

C-reactive protein

IL-6:

Interleukin-6

NMR:

Nuclear magnetic resonance

TNF-α:

Tumor necrosis factor-α

GFR:

Glomerular filtration rate

ANOVA:

Analysis of variance

CHF:

Congestive heart failure

References

  1. Fraze, T.K. (Thomson Reuters), Jiang, H.J. (AHRQ), and Burgess, J. 2008. (Thomson Reuters). Hospital Stays for Patients with Diabetes. HCUP Statistical Brief #93. August 2010. Agency for Healthcare Research and Quality, Rockville, MD. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb93.pdf.

  2. Umpierrez, G.E., R. Hellman, M.T. Korytkowski, M. Kosiborod, G.A. Maynard, V.M. Montori, J.J. Seley, and G. Van den Berghe. 2012. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline; Endocrine Society. Journal of Clinical Endocrinology and Metabolism 97(1): 16–38.

    Article  CAS  PubMed  Google Scholar 

  3. Umpierrez, G.E., S.D. Isaacs, N. Bazargan, X. You, L.M. Thaler, and A.E. Kitabchi. 2002. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. Journal of Clinical Endocrinology and Metabolism 87(3): 978–82.

    Article  CAS  PubMed  Google Scholar 

  4. Menzin, J., J.R. Korn, J. Cohen, F. Lobo, B. Zhang, M. Friedman, and P.J. Neumann. 2010. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus. Journal of Managed Care Pharmacy 16(4): 264–75.

    PubMed  Google Scholar 

  5. Falciglia, M., R.W. Freyberg, P.L. Almenoff, D.A. D’Alessio, and M.L. Render. 2009. Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis. Critical Care Medicine 37(12): 3001–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Pickup, J.C., and M.A. Crook. 1998. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41: 1241–8.

    Article  CAS  PubMed  Google Scholar 

  7. Clement, S., S.S. Braithwaite, M.F. Magee, A. Ahmann, E.P. Smith, R.G. Schafer, I.B. Hirsch, and American Diabetes Association Diabetes in Hospitals Writing Committee. 2004. Management of diabetes and hyperglycemia in hospitals. Diabetes Care 27(2): 553–91.

    Article  PubMed  Google Scholar 

  8. Gabay, C., and I. Kushner. 1999. Acute-phase proteins and other systemic responses to inflammation. New England Journal of Medicine 340: 448–54.

    Article  CAS  PubMed  Google Scholar 

  9. Ceciliani, F., and V. Pocacqua. 2007. The acute phase protein alpha1-acid glycoprotein: a model for altered glycosylation during diseases. Current Protein and Peptide Science 8: 91–108.

    Article  CAS  PubMed  Google Scholar 

  10. Dijk, W., G. Turner, and A. Mackiewicz. 1994. Changes in glycosylation of acute-phase proteins in health and disease: occurrence, regulation and function. Glycoconjugate Journal 1: 5–14.

    Article  CAS  Google Scholar 

  11. Bell, J.D., J.C. Brown, J.K. Nicholson, and P.J. Sadler. 1987. Assignment of resonances for ‘acute-phase’ glycoproteins in high resolution proton NMR spectra of human blood plasma. FEBS Letters 215: 311–5.

    Article  CAS  PubMed  Google Scholar 

  12. Otvos J, Shalaurova I, Wolak-Dinsmore J, Matyus S. 2013. GlycA and GlycB: novel NMR markers of systemic inflammation. American Association of Clinical Chemistry Poster #B-255.

  13. Akinkuolie A, Pradhan AD, Ridker PM, Mora S. 2013. Novel protein glycan derived biomarker is associated with incident diabetes. American Heart Association Poster 18807.

  14. Akinkuolie A.O., Buring J.E., Ridker P.M., Mora S. 2013. Novel protein glycan derived marker of systemic inflammation is associated with incident cardiovascular disease. American Heart Association, Poster 18739.

  15. Kriat, M., J. Vion-Dury, R. Fayre, D. Maraninchi, J.R. Harlé, S. Confort-Gouny, M. Sciaky, E. Fontanarava, P. Viout, and P.J. Cozzone. 1991. Variations of plasma sialic acid and N-acetylglucosamine levels in cancer, inflammatory diseases and bone marrow transplantation: a proton NMR spectroscopy study. Biochimie 73: 99–104.

    Article  CAS  PubMed  Google Scholar 

  16. Dungan, K.M., C. Sagrilla, M. Abdel-Rasoul, and K. Osei. 2013. Prandial insulin dosing using the carbohydrate counting technique in hospitalized patients with type 2 diabetes. Diabetes Care 36(11): 3476–82.

  17. Dungan K.M., Osei K., Gaillard T., Moore J., Binkley P. 2014. A comparison of continuous intravenous insulin and subcutaneous insulin among patients with type 2 diabetes and congestive heart failure exacerbation. Diabetes Metab Res Rev in press.

  18. Modification of Diet in Renal Disease Study Group. 1999. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Annals of Internal Medicine 130(6): 461–70.

  19. Braunwald, E. 2008. Biomarkers in heart failure. New England Journal of Medicine 358: 2148–2159.

  20. Burger, A.J., and D. Aronson. 2001. Blunted sympathetic response in diabetic patients with decompensated congestive heart failure. International Journal of Cardiology 81: 243–249.

    Article  CAS  PubMed  Google Scholar 

  21. Romeo, R., C. Scalisi, L. Tafuri, A. Romeo, D. Maugeri, and R. Sorace. 2010. Different characteristics of chronic heart failure (CHF) in elderly diabetics and non-diabetics. Archives of Gerontology and Geriatrics 50(1): 101–4.

  22. Jankowska, E.A., P. Ponikowski, M.F. Piepoli, W. Banasiak, S.D. Anker, and P.A. Poole-Wilson. 2006. Autonomic imbalance and immune activation in chronic heart failure—pathophysiological links. Cardiovascular Research 70: 434–445.

  23. Gruzdeva, O., E. Uchasova, Y. Dyleva, E. Belik, E. Shurygina, and O. Barbarash. 2013. Insulin resistance and inflammation markers in myocardial infarction. Journal of Inflammation Research 6: 83–90.

    PubMed Central  CAS  PubMed  Google Scholar 

  24. Heo, J.M., J.H. Park, J.H. Kim, S.H. You, J.S. Kim, C.M. Ahn, S.J. Hong, K.H. Shin, and D.S. Lim. 2012. Comparison of inflammatory markers between diabetic and nondiabetic ST segment elevation myocardial infarction. Journal of Cardiology 60(3): 204–9.

    Article  PubMed  Google Scholar 

  25. Liao, M.T., C.C. Sung, K.C. Hung, C.C. Wu, L. Lo, and K.C. Lu. 2012. Insulin resistance in patients with chronic kidney disease. Journal of Biomedicine and Biotechnology 2012: 691369.

    PubMed Central  PubMed  Google Scholar 

  26. Karavanaki, K., K. Kakleas, S. Georga, A. Bartzeliotou, G. Mavropoulos, M. Tsouvalas, A. Vogiatzi, I. Papassotiriou, and C. Karayianni. 2012. Plasma high sensitivity C-reactive protein and its relationship with cytokine levels in children with newly diagnosed type 1 diabetes and ketoacidosis. Clinical Biochemistry 45(16–17): 1383–8.

    Article  CAS  PubMed  Google Scholar 

  27. Turina, M., D.E. Fry, and H.C. Polk Jr. 2005. Acute hyperglycemia and the innate immune system: clinical, cellular, and molecular aspects. Critical Care Medicine 33(7): 1624–33.

    Article  PubMed  Google Scholar 

  28. Fantin Sde, S., M.V. Wainstein, C.A. Polanczyk, P. Ledur, C.M. Lazzari, C. Klein, F.S. Hackenhaar, M.S. Benfato, and B.D. Schaan. 2011. Inflammatory and oxidative stress markers after intravenous insulin in percutaneous coronary intervention with stent in type 2 diabetes mellitus: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism 96(2): 478–85.

    Article  PubMed  Google Scholar 

  29. Bree, F., G. Houin, J. Barre, J.L. Moretti, V. Wirquin, and J.P. Tillement. 1986. Pharmacokinetics of intravenously administered 125I-labelled human alpha 1-acid glycoprotein. Clinical Pharmacokinetics 11(4): 336–342.

    Article  CAS  PubMed  Google Scholar 

  30. Jones, E.A., J. Vergalla, C.J. Steer, P.R. Bradley-Moore, and J.M. Vierling. 1978. Metabolism of intact and desialylated alpha 1-antitrypsin. Clinical Science and Molecular Medicine 55(2): 139–48.

    CAS  PubMed  Google Scholar 

  31. Kormoczi, G.F., M.D. Saemann, C. Buchta, et al. 2006. Influence of clinical factors on the haemolysis marker haptoglobin. European Journal of Clinical Investigation 36: 202–209.

    Article  CAS  PubMed  Google Scholar 

  32. Ho, K.M., and J. Lipman. 2009. An update on C-reactive protein for intensivists. Anaesthesia and Intensive Care 37(2): 234–41.

    CAS  PubMed  Google Scholar 

  33. Sidhu, R.S., and A.P. Bollon. 1993. Tumor necrosis factor activities and cancer therapy—a perspective. Pharmacology and Therapeutics 57(1): 79–128.

    Article  CAS  PubMed  Google Scholar 

  34. Oda, S., H. Hirasawa, H. Shiga, K. Nakanishi, K. Matsuda, and M. Nakamua. 2005. Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome (SIRS)/sepsis. Cytokine 29(4): 169–75.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The project was supported by the OSU Clinical and Translational Research Center, award number UL1RR025755 from the National Center for Research Resources; by NIH grant numbers K23DK080891 and R21DK081877; and Novo Nordisk. The GlycA analyses were performed by LipoScience, Inc. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health or other affiliated parties.

Conflict of Interest

K.D. reports research funding from Merck, Mylan, Astra Zeneca, Glaxo Smith-Kline, and Bristol-Myers Squibb and advisory board activities with Eli Lilly and LipoScience. K.O. and P.B. have nothing to report.

Author information

Authors and Affiliations

  1. Division of Endocrinology, Diabetes and Metabolism, The Ohio State University, 5th Floor McCampbell Hall, 1581 Dodd Drive, Columbus, OH, 43210-1296, USA

    Kathleen Dungan & Kwame Osei

  2. Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, USA

    Philip Binkley

  3. Division of Cardiovascular Medicine, The Ohio State University, Columbus, OH, USA

    Philip Binkley

Authors
  1. Kathleen Dungan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philip Binkley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kwame Osei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kathleen Dungan.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dungan, K., Binkley, P. & Osei, K. GlycA is a Novel Marker of Inflammation Among Non-Critically Ill Hospitalized Patients with Type 2 Diabetes. Inflammation 38, 1357–1363 (2015). https://doi.org/10.1007/s10753-014-0107-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10753-014-0107-8

KEY WORDS

Search

Navigation